<DOC>
	<DOC>NCT02048410</DOC>
	<brief_summary>Probiotics have been proposed for the treatment of dyslipidemia. the investigators aimed to evaluate efficacy, tolerability and safety of a new symbiotic formulation containing a combination of probiotic and prebiotics and amine in the treatment of children affected by familial hypercholesterolemia (FH).</brief_summary>
	<brief_title>Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia</brief_title>
	<detailed_description>FH subjects, aged 6-12 years, consecutively observed a Tertiary Center for Pediatric Nutrition were randomly allocated to two groups of intervention for 6 months: active group, received a low saturated fats diet plus the symbiotic (2.5×109cfu, bid) for 6 months; control group, received low saturated fats diet alone. All children received written indications for low saturated fats diet. The plasmatic lipid profile was assessed by peripheral blood sampling at T0 and T1.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>aged ≥ 6 and ≤ 12 years. Diagnosis of hypercholesterolemia (LDL cholesterol&gt; 140 mg / dl) Each patient must have shown resistance to dietary therapy lasting at least 612 months. Age &lt;6 or&gt; 12 years. Patients undergoing drug treatment for hypercholesterolemia. Any medical condition that may interfere with participation in this study Participation in clinical trials still in progress. Taking pre / probiotics for more than 7 days in the 6 months prior to enrollment</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>